Prognostic value of chromogranin A at admission in critically ill patients: A cohort study in a medical intensive care unit

Clinical Chemistry

Volumn 54, Issue 9, 2008, Pages 1497-1503

  Zhang, Dan ^a,b,c   Lavaux, Thomas ^a,d   Voegeli, Anne Claire ^d   Lavigne, Thierry ^a,d   Castelain, Vincent ^a,d   Meyer, Nicolas ^a,d   Sapin, Rémy ^d   Aunis, Dominique ^b   Metz Boutigue, Marie Hélène ^b   Schneider, Francis ^a,d  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b INSERM   (France)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHROMOGRANIN A; CREATININE; PROCALCITONIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOGENIC SHOCK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HUMAN; INDEPENDENT VARIABLE; INTENSIVE CARE UNIT; LINEAR REGRESSION ANALYSIS; LOGISTIC ORGAN DYSFUNCTION SYSTEM SCORE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; SIMPLIFIED ACUTE PHYSIOLOGIC SCORE II; SURVIVOR; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHROMOGRANIN A; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT ADMISSION; PROGNOSIS; SURVIVAL RATE;

EID: 51349116092     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.102442     Document Type: Article

References (39)

1. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965;97:40C-1C.
2. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-49.
3. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992;41:9-18.
4. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002;23:967-74.
5. Cryer PE, Wortsman J, Shah SD, Nowak RM, Deftos LJ. Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 1991;260:E243-6.
6. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984;311:764-70.
7. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145-51.
8. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993;32:161-5.
9. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 1990;85:1555-9.
10. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109-17.
11. Rangon CM, Haik S, Faucheux BA, Metz-Boutigue MH, Fierville F, Fuchs JP, et al. Different chromogranin immunoreactivity between prion and a-beta amyloid plaque. Neuroreport 2003;14:755-8.
12. Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med 2003;114:25-30.
13. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 2006;152:927.e1-6.
14. Baue AE, Durham R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 1998;10:79-89.
15. Tamura DY, Moore EE, Partrick DA, Johnson JL, Offner PJ, Silliman CC. Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock 2002;17:269-73.
16. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150:299-303.
17. Vassault A, Cherruau B, Labbe D, Alabrune B, Baltassat P, Bonete R, et al. [Serum creatinine assay: results of a multicentric study with 16 analytical systems.] Ann Biol Clin (Paris) 1992;50:81-95. [French]
18. Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 1999;79:65-71.
19. Steinbach G, Rau B, Debard AL, Javourez JF, Bienvenu J, Ponzio A, et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 2004;42:440-9.
20. Giovanella L, La Rosa S, Ceriani L, Uccella S, Erba P, Garancini S. Chromogranin A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999;14:160-6.
21. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
22. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 1976;295:1404-13.
23. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
24. Timsit JF, Fosse JP, Troche G, De Lassence A, Alberti C, Garrouste-Orgeas M, et al. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med 2002;30:2003-13.
25. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955-64.
26. Tramonti G, Ferdeghini M, Annichiarico C, Norpoth M, Donadio C, Bianchi R, Bianchi C. Relationship between renal function and blood level of chromogranin A. Ren Fail 2001;23:449-57.
27. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219-23.
28. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Zwiller J, Revel MO, Aunis D, Bader MF. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem 2001;276:13113-20.
29. Kingham PJ, Pocock JM. Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarisation and the permeability transition but not by cytochrome c release. J Neurochem 2000;74:1452-62.
30. Hooper C, Pocock JM. Chromogranin A activates diverse pathways mediating inducible nitric oxide expression and apoptosis in primary microglia. Neurosci Lett 2007;413:227-32.
31. Tasiemski A, Hammad H, Vandenbulcke F, Breton C, Bilfinger TJ, Pestel J, Salzet M. Presence of chromogranin-derived antimicrobial peptides in plasma during coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002;100:553-9.
32. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997;100:1623-33.
33. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998;19:1241-8.
34. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005;115:1942-52.
35. Schetz MR, Van den Berghe G. Do we have reliable biochemical markers to predict the outcome of critical illness? Int J Artif Organs 2005;28:1197-210.
36. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17.
37. Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006;97:503-8.
38. Lee YJ, Park CH, Yun JW, Lee YS. Predictive comparisons of procalcitonin (PCT) level, arterial ketone body ratio (AKBR), APACHE III score and multiple organ dysfunction score (MODS) in systemic inflammatory response syndrome (SIRS). Yonsei Med J 2004;45:29-37.
39. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and metaanalysis. Lancet Infect Dis 2007;7:210-7.